AUTHOR=Ringheim Garth E., Lee Lan , Laws-Ricker Lynn , Delohery Thomas , Liu Li , Zhang Donghui , Colletti Nicholas , Soos Timothy J., Schroeder Kendra , Fanelli Barbara , Tian Nian , Arendt Christopher W., Iglesias-Bregna Deborah , Petty Margaret , Ji Zhongqi , Qian George , Gaur Rajula , Weinstock Daniel , Cavallo Jean , Telsinskas Juventas , McMonagle-Strucko Kathleen TITLE=Teriflunomide Attenuates Immunopathological Changes in the Dark Agouti Rat Model of Experimental Autoimmune Encephalomyelitis JOURNAL=Frontiers in Neurology VOLUME=4 YEAR=2013 URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2013.00169 DOI=10.3389/fneur.2013.00169 ISSN=1664-2295 ABSTRACT=

Teriflunomide is an oral disease-modifying therapy recently approved in several locations for relapsing-remitting multiple sclerosis. To gain insight into the effects of teriflunomide, immunocyte population changes were measured during progression of experimental autoimmune encephalomyelitis in Dark Agouti rats. Treatment with teriflunomide attenuated levels of spinal cord-infiltrating T cells, natural killer cells, macrophages, and neutrophils. Teriflunomide also mitigated the disease-induced changes in immune cell populations in the blood and spleen suggesting an inhibitory effect on pathogenic immune responses.